▲ BUY
9
/ 10
Conviction
$ Value
$1.7M
Shares
4,290
Price
$389
Filed
Aug 7
▶ Why this score? (9/10)
- ✓ Open market buy (+3)
- ✓ Trade value >= $1.0M (+2)
- ✓ C-suite insider (+2)
- ✓ Director (+1)
- ✓ Not a 10b5-1 plan (+1)
Insider
Name
Kewalramani Reshma
Title
CEO & President
CIK
0001735944
Roles
Director
Officer
Transaction Details
Transaction Date
2025-08-06
Code
P
Table
Non-Derivative
Ownership
Direct
Equity Swap
No
Shares After
110,258
Footnotes
Open market purchases reported on this line occurred at a weighted average price of $389.08 (range $388.71 to $389.43). | Dr. Kewalramani undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares purchased at each separate price. | Open market purchases reported on this line occurred at a weighted average price of $389.95 (range $389.72 to $390.53).
Filing Info
Kewalramani Reshma's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-01-22 | VRTX | A | $0 |
| 2026-01-22 | VRTX | A | $0 |
| 2025-08-06 | VRTX | ▲ | $1.7M |
| 2025-08-06 | VRTX | ▲ | $2.2M ★ |
Other Insiders at VRTX (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
| SACHS BRUCE I | — | — | 2026-04-15 |
|
WAGNER CHARLES F JR
EVP, CO & FO
|
— | — | 2026-01-22 |
|
LEIDEN JEFFREY M
Executive Chairman
|
— | — | 2026-01-22 |
| Garber Alan M | — | — | 2026-04-15 |
|
Sachdev Amit
EVP Chief Patient & Ext Af Off
|
— | — | 2026-01-22 |
| Upadhyay Suketu | — | — | 2026-04-15 |
|
ALTSHULER DAVID
EVP, Chief Scientific Officer
|
— | — | 2026-01-22 |
|
Kewalramani Reshma
CEO & President
|
— | — | 2026-01-22 |
|
Biller Jonathan
EVP and Chief Legal Officer
|
— | $886K | 2026-02-11 |
|
Tatsis Ourania
EVP, Chief Reg. & Quality Off.
|
— | — | 2026-01-22 |
|
Bozic Carmen
EVP and CMO
|
— | $1.1M | 2026-03-27 |
|
Liu Joy
EVP and Chief Legal Officer
|
— | $439K | 2026-04-01 |
|
Ambrose Kristen
SVP & Chief Accounting Officer
|
— | $634K | 2026-02-11 |
|
Atkinson Edward Morrow III
EVP, Chief Technical Ops. Off.
|
— | $806K | 2026-02-11 |
|
McKechnie Duncan
EVP, Chief Commercial Officer
|
— | — | 2026-01-22 |
|
Bunnage Mark E.
EVP, Chief Scientific Officer
|
— | $931K | 2026-02-11 |